Cordyceps Sunshine Biotech Holdings (RAJAF) Other Accumulated Expenses (2022 - 2025)

Cordyceps Sunshine Biotech Holdings' Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $7892.0 for Q4 2025.

• In Q4 2025, Other Accumulated Expenses rose 51.01% year-over-year to $7892.0; the TTM figure through Dec 2025 stood at $7892.0 (up 51.01% YoY), while the FY2025 annual figure was $7892.0, up 51.01% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $7892.0, up from $5226.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.4 million in Q4 2022, with the low at $5226.0 in Q4 2024.
• The 3-year median for Other Accumulated Expenses is $7892.0 (2025), against an average of $463798.3.
• Peak annual rise in Other Accumulated Expenses reached 51.01% in 2025, while the deepest fall reached 51.01% in 2025.
• Cordyceps Sunshine Biotech Holdings' Other Accumulated Expenses stood at $1.4 million in 2022, then plunged by 99.62% to $5226.0 in 2024, then surged by 51.01% to $7892.0 in 2025.
• Business Quant data shows RAJAF's Other Accumulated Expenses at $7892.0 in Q4 2025, $5226.0 in Q4 2024, and $1.4 million in Q4 2022.